ÌÇÐÄ´«Ã½

By defining the clinical and genetic factors that predict treatment response, Vanderbilt investigators aim to personalize therapy for a common heart complication in preterm infants.

Vanderbilt University’s F. Peter (Fred) Guengerich, PhD, and Elaine Sanders-Bush, PhD, are among 22 prominent scientists named this week to the inaugural class of fellows of the American Society for Pharmacology and Experimental Therapeutics (ASPET).

Live cell imaging studies have revealed that microvilli — finger-like protrusions on the surface of epithelial cells — move and collide as they form the brush border.

VUMC's Eric Gamazon has received a Genomic Innovator Award from the National Human Genome Research Institute, part of the NIH.

An analysis of more than 140,000 people of European ancestry has identified blood protein biomarkers associated with prostate cancer risk.

A single pill containing low doses of three medications to treat high blood pressure and one to lower cholesterol reduced the estimated risk of cardiovascular disease by 25%, according to a VUMC study.

Studies of relational memory function may reveal novel mechanisms for therapeutic intervention for patients in the early stages of psychosis.

A protein with important functions in astrocytes — star-shaped brain support cells — may alter neuronal excitability and contribute to seizure activity, Vanderbilt researchers report.

Vanderbilt researchers have discovered that a protein called SGK1 in immune cells is activated by sodium, leading to the development of salt-sensitive hypertension.

Understanding the dynamic regulation of cytoskeletal microtubules may suggest new ways to treat disorders ranging from Alzheimer's disease to cancer.

According to a new study, the tiny zebrafish may hold the secret to regenerating damaged retinas in humans.

Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago.

Jason MacGurn and colleagues have characterized a “rheostat” that sets WNT pathway signaling in breast cancer cells.

Colorectal cancer researchers from Vanderbilt-Ingram Cancer Center (VICC) have been awarded a Specialized Program of Research Excellence grant from the National Cancer Institute (NCI).

Gene variants associated with cancer risk appear to contribute to carcinogenesis by regulating target genes that in turn promote the generation of mutations.

Vanderbilt’s Bruce Carter and colleagues have discovered how genetic changes in the protein PMP22 may contribute to a disease of peripheral nerves.

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Breast cancer researchers at Vanderbilt-Ingram Cancer Center have secured a fourth round of continuous Specialized Program of Research Excellence funding.

Researchers have made a paradigm-shifting discovery that could lead to new treatments, better health and longer life for patients with Type 1 diabetes.

A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.